STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non–Small Cell Lung Cancer With No Actionable Gene Alterations

  • Delvys Rodriguez-Abreu
  • , Joaquim Bosch-Barrera
  • , Jhanelle E. Gray
  • , Myung Ju Ahn
  • , Melissa Johnson
  • , Xinwei Yu
  • , Saad Mohammad
  • , Xueying Chen
  • , Trever Todd
  • , Jongseok Kim
  • , Martin Reck

Research output: Contribution to journal › Article › peer-review

6   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non–Small Cell Lung Cancer With No Actionable Gene Alterations'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science